MYH9 and deafness: This interaction, which we demonstrated in cisplatin-treated renal proximal tubular cells, unifies the shared adverse effect profile of a number of drugs that cause both nephrotoxicity and ototoxicity with MYH9-related genetic diseases, which manifest with thrombocytopenia, deafness, and renal failure (31).